Xie Xueping, Chen Jie, Que Rongcai, Xu Chang
Department of Rehabilitation, The Second Hospital of Longyan Longyan 364000, Fujian, China.
School of Biological Engineering, Wuhan Polytechnic Wuhan 430074, Hubei, China.
Am J Transl Res. 2024 Sep 15;16(9):5011-5019. doi: 10.62347/TCXI4740. eCollection 2024.
To analyze the effect of tobramycin dexamethasone combined with pranoprofen on middle-aged and elderly patients after cataract surgery.
In this retrospective study, the clinical data from 108 middle-aged and elderly patients who had cataract surgery in the Second Hospital of Longyan between January 2021 and December 2023 were collected. The patients were divided into two groups based on treatment methods, a control group (n=54) that received tobramycin dexamethasone treatment, and an observation group (n=54) that treated with additional pranoprofen. The treatment effects in the two groups were compared.
Significant differences were observed between the groups at 1 day, 1 week, 3 weeks, and 5 weeks post-treatment in terms of ocular symptom scores, signs scores, and intraocular pressure levels (all P < 0.05). The observation group demonstrated lower levels of inflammatory markers post-treatment (P < 0.05). Additionally, at 1 week, 3 weeks and 5 weeks after treatment, significant differences were noted in anterior chamber flare value, best-corrected visual acuity (BCVA), macular center thickness, degree of corneal edema, and posterior lens capsular opacity grading scores (all P < 0.05). The incidence of increased intraocular pressure and conjunctival congestion was 3.7% in the observation group, slightly lower than 7.41% in the control group (P > 0.05).
The combination of pranoprofen and tobramycin dexamethasone can improve the inflammatory reaction, ocular symptoms, anterior chamber flare value, macular center thickness, corneal oedema, and clarity of the posterior lens capsule in middle-aged and elderly cataract patients. This regimen also helps restore intraocular pressure and visual acuity of the patients, with relatively low adverse reactions, indicating an ideal clinical outcome.
分析妥布霉素地塞米松联合普拉洛芬对中老年白内障患者术后的影响。
本回顾性研究收集了2021年1月至2023年12月在龙岩市第二医院行白内障手术的108例中老年患者的临床资料。根据治疗方法将患者分为两组,对照组(n = 54)接受妥布霉素地塞米松治疗,观察组(n = 54)在对照组基础上加用普拉洛芬治疗。比较两组的治疗效果。
治疗后1天、1周、3周和5周时,两组在眼部症状评分、体征评分和眼压水平方面存在显著差异(均P < 0.05)。观察组治疗后炎症标志物水平较低(P < 0.05)。此外,治疗后1周、3周和5周时,前房闪辉值、最佳矫正视力(BCVA)、黄斑中心厚度、角膜水肿程度和后囊膜混浊分级评分存在显著差异(均P < 0.05)。观察组眼压升高和结膜充血的发生率为3.7%,略低于对照组的7.41%(P > 0.05)。
普拉洛芬与妥布霉素地塞米松联合应用可改善中老年白内障患者的炎症反应、眼部症状、前房闪辉值、黄斑中心厚度、角膜水肿及后囊膜清晰度。该方案还有助于恢复患者的眼压和视力,不良反应相对较少,显示出理想的临床效果。